Evaluation of the nitrosamine impurities of <scp>ACE</scp> inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential
Jennifer Cheung(Pfizer (United States)), Maik Schuler(Pfizer (United States)), Raphael Nudelman(Teva Pharmaceuticals (Israel)), Andreas Czich(Sanofi (Germany)), Shaofei Zhang(Pfizer (United States)), Krista L. Dobo(Pfizer (United States)), Friedemann Schmidt(Sanofi (Germany)), Jan Wenzel(Sanofi (Germany))
Cited by 14
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
|Journal of Medicinal Chemistry|2006|141
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension
|Proceedings of the National Academy of Sciences|2005|132